TP53 mutation defines an immunogenic and lymphocytes infiltrated TME type in breast cancer and defines a low cytolytic T cell infiltration TME type in head and neck squamous cell carcinoma. This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.